Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23506334 | 1.00 | HPGD (0.48) | HPGDALDH1A1TP53SMN1; SMN2MAOB | |
| SCHEMBL23506229 | 0.95 | HPGD (0.50) | HPGDALDH1A1TP53SMN1; SMN2MAOB | |
| SCHEMBL21702237 | 0.95 | HPGD (0.50) | HPGDALDH1A1TP53SMN1; SMN2MAOB | |
| SCHEMBL23711629 | 0.95 | HPGD (0.50) | HPGDALDH1A1TP53SMN1; SMN2MAOB | |
| SCHEMBL23711720 | 0.94 | TDP1 (0.45) | HPGDALDH1A1TP53SMN1; SMN2RAB9A | |
| SCHEMBL23711763 | 0.94 | HDAC2 (0.41) | HPGDALDH1A1TP53SMN1; SMN2RAB9A | |
| SCHEMBL23711731 | 0.91 | HPGD (0.39) | HPGDALDH1A1TP53SMN1; SMN2CTSL | |
| SCHEMBL23711733 | 0.90 | TP53 (0.52) | HPGDALDH1A1TP53SMN1; SMN2RAB9A | |
| SCHEMBL23506457 | 0.89 | RAB9A (0.41) | HPGDALDH1A1TP53SMN1; SMN2MAOB | |
| SCHEMBL23711730 | 0.89 | CTSL (0.39) | HPGDALDH1A1TP53SMN1; SMN2CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021151387-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | 中国科学院上海药物研究所 | 2021-08-05 | — | — | WO | disclosed |
| WO-2020030143-A1 | KETOAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 中国科学院上海药物研究所 | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133600-A1 | PHARMACEUTICAL USE OF KETOAMIDE-BASED COMPOUND | CTSL, CTSV, CTSS | HPGD 1413/4885ALDH1A1 2113/4885TP53 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.